Abstract:Treating solid tumours with chimeric antigen receptors-modified T cells (CAR-T cells) has shown limited efficacy due to the lack of cancer-type specific antigens. Dinutuximab is a monoclonal antibody that recognizes a sphingolipid, disialoganglioside GD2, which has limited expression in normal tissues but is overexpressed in paediatric tumours, mainly neuroblastoma (NB) and diffuse intrinsic pontine glioma (DIPG) and other histone H3 K27M (H3K27M) mutated diffuse midline gliomas. Dinutuximab, an anti-GD2 antibody, is currently standard of care in the treatment of NB. We are contemplating the possibility of using Dinutuximab as target element for antiNB-CAR-T cells. Our group have explored the feasibility of producing CAR-T cells from peripheral blood (PB), post-apheresis CD45RA+ fraction and cord blood (CB) using similar protocols of T cell transduction and expansion ability as a way to favour the persistence of CAR-T cells in the host. Afterward, we performed a deeply characterization of phenotype and functionality of anti-FITC-CAR-T cells derived from different sources, and the cytotoxic effect against anti-GD2-FITC- NB labelled cell line. T cells purified from PB, CB and 45RA fraction after apheresis were cultured in vitro with cytokines IL-7+IL-15+IL- 21 to maintain early memory phenotypes as Naïve T cells (TN). A second generation lentiviral expression vector (LV) was used to generate second generation CARs (FITC-L-BBz CAR). After 48h of activation in culture with antiCD3/CD28 and cytokines, T cells were transduced with viral supernatants. Next, we performed a characterization of phenotype of anti-FITC-CAR-T cells by flow cytometry studying how the culture conditions enhanced a TN phenotype expressing CD45RA+ and CCR7+. Cytotoxic function of CAR-T cells was analysed in cocultures with LAN-1 NB cell line labelled with Dinutuximab conjugated with FITC. Preliminary results showed that culture condition with IL-7/15/21 maintained more primitive phenotypes in 45RA (71% TN CD4+ and 66% TN CD8+) and CB (60% of TN CD4+ and 77% of TN CD8+) derived T cells than PB T cells (only a 20% of TN CD4+ and TN CD8+). PB and CB-derived CAR-T cells showed higher cytolitic function than 45RA fraction, resulting in a 30% of dead cells in both cases in a 24h-culture assay. Both, PB and CB derived CAR-T cells showed the best CAR-T activation capacity with 19,6% of cells from PB and 33,9% of cells from CB expressing early activation markers as CD25 and CD134. In vivo experiments are currently on-going to test the efficacy of CAR-T cells in combination with GD2 treatment. Our strategy may complement the current use of Dinutuximab in the treatment of NB through its combination with a targeted CAR-T cell approach.

GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma.

GD2-specific chimeric antigen receptor-modified T cells for the treatment of refractory and/or recurrent neuroblastoma in pediatric patients

Polymorphonuclear myeloid-derived suppressor cells impair the anti-tumor efficacy of GD2.CAR T-cells in patients with neuroblastoma

GD2-targeting CAR T-cell therapy for patients with GD2+ medulloblastoma

Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors

Eighteen-year survival after GD2-directed Chimeric Antigen Receptor-Modified Immune Effector Cell Treatment for Neuroblastoma

GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas

Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers

Sequential intravenous and intracerebroventricular GD2-CAR T-cell therapy for H3K27M-mutated diffuse midline gliomas

Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers

Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I/II Trial

Safety and Antitumor Activity of GD2-Specific 4SCAR-T Cells in Patients with Glioblastoma

Bispecific GD2 x B7-H3 Antibody Improves Tumor Targeting and Reduces Toxicity while Maintaining Efficacy for Neuroblastoma

Use of anti-GD2 (Dinutuximab) as a target for CAR-T cells immunotherapy in neuroblastoma

CAR T-cell-mediated delivery of bispecific innate immune cell engagers for neuroblastoma

Autologous anti-GD2 CAR T cells efficiently target primary human glioblastoma

NK cells engineered to express a GD2-specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin

GD2-specific chimeric antigen receptor-modified T cells targeting retinoblastoma - assessing tumor and T cell interaction

Management of High-Risk Neuroblastoma with Soft-Tissue-Only Disease in the Era of Anti-GD2 Immunotherapy

Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group

Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy